BeOne Medicines Ltd. (ONC)
Automate Your Wheel Strategy on ONC
With Tiblio's Option Bot, you can configure your own wheel strategy including ONC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ONC
- Rev/Share 3.0041
- Book/Share 2.5175
- PB 7.7237
- Debt/Equity 0.2848
- CurrentRatio 1.9642
- ROIC -0.0931
- MktCap 25118596932.0
- FreeCF/Share -0.173
- PFCF -104.4567
- PE -68.8873
- Debt/Assets 0.1706
- DivYield 0
- ROE -0.1151
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ONC | RBC Capital Mkts | -- | Outperform | -- | $312 | April 7, 2025 |
| Upgrade | ONC | BofA Securities | Neutral | Buy | $207 | $320 | March 3, 2025 |
News
Cancer Stock Vaults 40% As Clinical Trial Shows 'Promise'; Sales Reach $1 Billion, Earnings To Triple
Published: June 05, 2025 by: Investors Business Daily
Sentiment: Positive
Cancer stock BeiGene renamed itself as BeOne. Shares have gained 40% year to date, outperforming the S&P 500.
Read More
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules: BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) in patients with advanced solid tumors, includi.
Read More
BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share 23 abstracts featuring new data across its hematology and solid tumor portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, May 30 – June 3, 2025. With two abstracts selected for rapid oral presentation, these data reflect the Company's vision to address cancer.
Read More
Undercovered Dozen: Richtech Robotics, Intesa Sanpaolo, BeiGene, Analog Devices +
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Neutral
The 'Undercovered' Dozen series highlights 12 lesser-covered stocks weekly, providing investment ideas and sparking community discussion on their potential. Graham Corporation and Legal & General Group Plc are recommended as buys due to strong balance sheets, strategic growth, and favorable market conditions. Butterfly Network, Hudson Pacific Properties, and B&G Foods are rated as holds, with potential for growth but facing significant challenges and uncertainties.
Read More
BeiGene, Ltd., Soon To Be BeOne Medicines: New Name And New Profit
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Positive
BeiGene, Ltd., soon to be BeOne Medicines, is a global oncology company with a strong focus on innovative cancer treatments, particularly Brukinsa and Tevimbra. Brukinsa, a BTK inhibitor, has shown impressive revenue growth and market share gains, with significant potential for future expansion and revenue generation. Tevimbra, while facing intense competition, shows promise with recent FDA approvals and ongoing trials targeting various cancers.
Read More
BeiGene, Ltd. (ONC) Q1 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
BeiGene, Ltd.
Read More
Chinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings Beat
Published: May 07, 2025 by: Benzinga
Sentiment: Negative
BeiGene Ltd. ONC stock is trading lower after the company reported mixed first-quarter 2025 financial results on Wednesday.
Read More
Compared to Estimates, BeiGene (ONC) Q1 Earnings: A Look at Key Metrics
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for BeiGene (ONC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
BeiGene Announces First Quarter 2025 Financial Results and Business Updates
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines, Ltd., today announced financial results and corporate updates from the first quarter 2025. “We delivered another exceptional quarter, achieving our first quarter of GAAP profitability with continued global revenue growth. In the U.S., BRUKINSA remains the leader in new chronic lymphocytic leukemia (CLL) patient starts across all line.
Read More
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene
Published: April 29, 2025 by: Business Wire
Sentiment: Neutral
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office (USPTO) rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC's (Pharmacyclics) U.S. Patent No. 11,672,803 (the ‘803 patent) that were challenged by BeiGene in a post-grant review (PGR) proceeding. On November 1, 2023, BeiGene filed a PGR pe.
Read More
BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit
Published: April 03, 2025 by: Benzinga
Sentiment: Negative
BeiGene Ltd ONC on Thursday announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer.
Read More
BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program
Published: April 03, 2025 by: Business Wire
Sentiment: Neutral
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer. The Independent Data Monitoring Committee recommended terminating the ongoing Phase 3 AdvanTIG-302 trial (NCT04746924) based on its findings as part of a pre.
Read More
BeiGene: Q4 Results Impress With Positive Earnings Expected In 2025
Published: February 28, 2025 by: Seeking Alpha
Sentiment: Positive
BeiGene is a BUY due to Tevimbra's approval and Brukinsa's growing sales, leading to anticipated positive earnings in 2025. Q4 and full-year 2024 revenues surged to $1.1B and $3.8B respectively, with a 78% and 55% increase, positioning BeiGene for profitability. BeiGene announced a name change to BeOne Medicines, transitioning from historical losses to profitability, and potentially attracting new buyers.
Read More
The Billionaire Baker Brothers Just Made This Big Biotech Stock Move
Published: February 28, 2025 by: 24/7 Wall Street
Sentiment: Neutral
If you're interested in biotechnology stocks, billionaires Julian and Felix Baker are the ones to turn to.
Read More
BeiGene (ONC) Soars 3.2%: Is Further Upside Left in the Stock?
Published: February 21, 2025 by: Zacks Investment Research
Sentiment: Positive
BeiGene (ONC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Read More
HRMY or ONC: Which Is the Better Value Stock Right Now?
Published: February 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and BeiGene, Ltd. (ONC). But which of these two stocks is more attractive to value investors?
Read More
About BeOne Medicines Ltd. (ONC)
- IPO Date 2016-02-02
- Website https://beonemedicines.com/
- Industry Medical - Pharmaceuticals
- CEO Mr. John V. Oyler
- Employees 11000